| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 87 | 1.090 |
Why?
|
| Lymphedema | 2 | 2016 | 4 | 0.940 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 131 | 0.850 |
Why?
|
| Image Enhancement | 2 | 2020 | 42 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 856 | 0.650 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2020 | 8 | 0.650 |
Why?
|
| Artifacts | 1 | 2020 | 29 | 0.640 |
Why?
|
| Movement | 1 | 2020 | 104 | 0.620 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 32 | 0.600 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 16 | 0.520 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 68 | 0.510 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 133 | 0.480 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2014 | 2 | 0.430 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 9 | 0.430 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 39 | 0.420 |
Why?
|
| Neuronal Plasticity | 1 | 2014 | 38 | 0.420 |
Why?
|
| Contrast Media | 4 | 2020 | 59 | 0.410 |
Why?
|
| Brain | 2 | 2020 | 1203 | 0.400 |
Why?
|
| Neurons | 1 | 2014 | 273 | 0.360 |
Why?
|
| Female | 17 | 2017 | 12901 | 0.270 |
Why?
|
| Humans | 19 | 2020 | 22838 | 0.260 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2017 | 48 | 0.260 |
Why?
|
| Male | 16 | 2017 | 12415 | 0.250 |
Why?
|
| Coronary Thrombosis | 3 | 2015 | 6 | 0.220 |
Why?
|
| Coronary Vessels | 2 | 2015 | 33 | 0.220 |
Why?
|
| Coronary Angiography | 5 | 2015 | 68 | 0.200 |
Why?
|
| Rhinitis | 2 | 2016 | 136 | 0.200 |
Why?
|
| Mice | 3 | 2017 | 1264 | 0.200 |
Why?
|
| Asthma | 2 | 2016 | 152 | 0.200 |
Why?
|
| Sinusitis | 2 | 2016 | 151 | 0.200 |
Why?
|
| Animals | 5 | 2018 | 3311 | 0.190 |
Why?
|
| Middle Aged | 12 | 2017 | 7869 | 0.180 |
Why?
|
| Child, Preschool | 3 | 2017 | 566 | 0.170 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 124 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 573 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 95 | 0.160 |
Why?
|
| Aged | 10 | 2017 | 7415 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 591 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2017 | 138 | 0.150 |
Why?
|
| Fibrosis | 2 | 2016 | 30 | 0.150 |
Why?
|
| Child | 3 | 2017 | 1154 | 0.150 |
Why?
|
| Infant | 2 | 2017 | 482 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 441 | 0.140 |
Why?
|
| Adult | 8 | 2016 | 6892 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2017 | 2929 | 0.140 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 9 | 0.140 |
Why?
|
| Alzheimer Disease | 2 | 2017 | 1320 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 11 | 0.140 |
Why?
|
| Adolescent | 3 | 2017 | 1875 | 0.140 |
Why?
|
| Drug-Eluting Stents | 2 | 2015 | 14 | 0.130 |
Why?
|
| Autophagy | 1 | 2018 | 30 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 174 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2017 | 34 | 0.130 |
Why?
|
| Leucovorin | 1 | 2017 | 8 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 49 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2017 | 15 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2017 | 21 | 0.130 |
Why?
|
| Mice, Nude | 1 | 2017 | 25 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2017 | 46 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 21 | 0.130 |
Why?
|
| Random Allocation | 1 | 2017 | 103 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 87 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 5 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 6 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 34 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2016 | 15 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 373 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 18 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 21 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2017 | 61 | 0.120 |
Why?
|
| Turbinates | 1 | 2016 | 4 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 22 | 0.120 |
Why?
|
| Rhinoplasty | 1 | 2016 | 10 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 83 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2016 | 49 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 526 | 0.120 |
Why?
|
| Nasal Polyps | 1 | 2016 | 51 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 13 | 0.110 |
Why?
|
| Absorbable Implants | 1 | 2015 | 17 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2015 | 22 | 0.110 |
Why?
|
| Sirolimus | 1 | 2015 | 20 | 0.110 |
Why?
|
| Polymers | 1 | 2015 | 36 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 20 | 0.110 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2014 | 2 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2016 | 78 | 0.110 |
Why?
|
| Self Administration | 1 | 2014 | 16 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2014 | 1 | 0.110 |
Why?
|
| Nitroprusside | 1 | 2014 | 6 | 0.110 |
Why?
|
| Amphetamine | 1 | 2014 | 5 | 0.110 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2014 | 12 | 0.110 |
Why?
|
| Adenosine | 1 | 2014 | 8 | 0.110 |
Why?
|
| Cocaine | 1 | 2014 | 31 | 0.100 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 16 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 153 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 132 | 0.100 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 1 | 0.100 |
Why?
|
| Corpus Striatum | 1 | 2014 | 63 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 24 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 235 | 0.100 |
Why?
|
| Angiography | 1 | 2013 | 25 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 45 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 289 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 34 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 37 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 232 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 40 | 0.090 |
Why?
|
| Mutation | 1 | 2014 | 329 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2017 | 2966 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2012 | 69 | 0.090 |
Why?
|
| Stents | 1 | 2012 | 75 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 146 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 536 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2016 | 1490 | 0.080 |
Why?
|
| Receptors, Scavenger | 1 | 2009 | 2 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 4 | 0.080 |
Why?
|
| Introns | 1 | 2009 | 14 | 0.080 |
Why?
|
| Aging | 1 | 2017 | 1102 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 480 | 0.080 |
Why?
|
| Time Factors | 3 | 2015 | 1259 | 0.060 |
Why?
|
| Hepatic Artery | 1 | 2005 | 3 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 55 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 53 | 0.060 |
Why?
|
| ROC Curve | 2 | 2016 | 121 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 439 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 3718 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 373 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 800 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1407 | 0.040 |
Why?
|
| Risk Factors | 2 | 2015 | 1966 | 0.040 |
Why?
|
| Autophagy-Related Proteins | 1 | 2018 | 4 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2018 | 11 | 0.030 |
Why?
|
| Doxycycline | 1 | 2018 | 16 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2017 | 10 | 0.030 |
Why?
|
| Apathy | 1 | 2017 | 2 | 0.030 |
Why?
|
| Anisotropy | 1 | 2017 | 35 | 0.030 |
Why?
|
| Ischemia | 1 | 2017 | 22 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 1 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2016 | 5 | 0.030 |
Why?
|
| Gadolinium | 1 | 2016 | 3 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 28 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 59 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 17 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 19 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 19 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 11 | 0.030 |
Why?
|
| Smell | 1 | 2016 | 13 | 0.030 |
Why?
|
| White Matter | 1 | 2017 | 107 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 25 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 72 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 310 | 0.030 |
Why?
|
| Myocardium | 1 | 2016 | 102 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 244 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 137 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 162 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 320 | 0.030 |
Why?
|
| Neointima | 1 | 2015 | 1 | 0.030 |
Why?
|
| Coronary Restenosis | 1 | 2015 | 10 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 200 | 0.030 |
Why?
|
| China | 1 | 2015 | 45 | 0.030 |
Why?
|
| Chromium Alloys | 1 | 2015 | 28 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 1 | 2014 | 1 | 0.030 |
Why?
|
| Endoscopy | 1 | 2016 | 165 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 536 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 86 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 195 | 0.030 |
Why?
|
| Flushing | 1 | 2014 | 3 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 5 | 0.030 |
Why?
|
| Hyperemia | 1 | 2014 | 2 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 865 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2014 | 54 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 36 | 0.030 |
Why?
|
| Paranasal Sinuses | 1 | 2014 | 61 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dyspnea | 1 | 2014 | 35 | 0.030 |
Why?
|
| Dementia | 1 | 2017 | 388 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2015 | 384 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 42 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 315 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 2012 | 2 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 162 | 0.020 |
Why?
|
| Heparin | 1 | 2012 | 22 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 16 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 39 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 623 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 1408 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 1645 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 349 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 125 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 948 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 727 | 0.020 |
Why?
|
| Chemokine CXCL16 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 41 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 75 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 47 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 45 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 168 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 248 | 0.020 |
Why?
|
| Liver Circulation | 1 | 2005 | 5 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2005 | 9 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 52 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 23 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 165 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 210 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 102 | 0.010 |
Why?
|